QuidelOrtho Valuation

Is QL1A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of QL1A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€105.55
Fair Value
60.4% undervalued intrinsic discount
7
Number of Analysts


Key Valuation Metric

Which metric is best to use when looking at relative valuation for QL1A?

Key metric:

The above table shows the Price to Sales ratio for QL1A. This is calculated by dividing QL1A's market cap by their current revenue.
What is QL1A's PS Ratio?
PS Ratio1x
SalesUS$2.82b
Market CapUS$2.92b

Price to Sales Ratio vs Peers

How does QL1A's PS Ratio compare to its peers?

The above table shows the PS ratio for QL1A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
AFX Carl Zeiss Meditec
2.5x6.3%€5.2b
EUZ Eckert & Ziegler
4.1x5.4%€1.1b
DRW3 Drägerwerk KGaA
0.3x3.3%€966.0m
SBS Stratec
1.7x6.1%€431.5m
QL1A QuidelOrtho
1x1.0%€2.9b


Price to Sales Ratio vs Industry

How does QL1A's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x3.3%US$1.00b
PHH2 Paul Hartmann
0.3xn/aUS$821.02m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
QL1A 1.0xIndustry Avg. 4.1xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies


Price to Sales Ratio vs Fair Ratio

What is QL1A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QL1A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio1.4x


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 7 Analysts
€49.19
Fair Value
15.0% undervalued intrinsic discount
7
Number of Analysts


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 14:05
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

QuidelOrtho Corporation is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Ishan MajumdarBaptista Research
Mark MassaroCanaccord Genuity